ImmunoGen Announces Webcast of Panel Discussion at Upcoming Cowen 42nd Annual Health Care Conference

Rhea-AI Summary

ImmunoGen, Inc. (NASDAQ: IMGN) announced that Mark Enyedy, President and CEO, will participate in the ovarian cancer panel at the Cowen 42nd Annual Health Care Conference on March 9, 2022, from 12:50 to 1:50 PM ET. The event will be available via a live webcast on the company's website, with a replay accessible afterward. ImmunoGen focuses on developing antibody-drug conjugates (ADCs) aimed at improving cancer treatment outcomes, emphasizing their commitment to providing enhanced patient care with targeted therapies.

Positive

• Participation in a high-profile health care conference could increase visibility and credibility for ImmunoGen.
• Continued focus on developing advanced antibody-drug conjugates (ADCs), signaling ongoing innovation in cancer treatment.

Negative

• None.

WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, President and CEO, will participate in the ovarian cancer panel discussion at the upcoming Cowen 42nd Annual Health Care Conference. The panel is scheduled for March 9, 2022 from 12:50 – 1:50pm ET.

A webcast of the panel will be accessible through the “Investors and Media” section of the Company’s website, www.immunogen.com. Following the live webcast, a replay will be available at the same location.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220223005063/en/

INVESTOR RELATIONS AND MEDIA CONTACTS

ImmunoGen

Courtney O'Konek

781-895-0600

courtney.okonek@immunogen.com

OR

FTI Consulting

Robert Stanislaro

212-850-5657

robert.stanislaro@fticonsulting.com

Source: ImmunoGen, Inc.

FAQ

What is ImmunoGen's involvement in the Cowen 42nd Annual Health Care Conference?

ImmunoGen's President and CEO, Mark Enyedy, will participate in the ovarian cancer panel discussion at the conference on March 9, 2022.

Where can I watch the ImmunoGen panel discussion?

The panel discussion can be accessed via a live webcast on the Investors and Media section of ImmunoGen's website.

What is ImmunoGen's focus in cancer treatment?

ImmunoGen is focused on developing antibody-drug conjugates (ADCs) to improve outcomes for cancer patients.